GLIX1 Development - A joint venture with Hemispherian AS was established in September 2025 to develop GLIX1 for glioblastoma and other indications, with initial economic stakes of Hemispherian at 60% and BioLineRx at 40%, potentially increasing to 70% for BioLineRx [7, 8] - GLIX1 is set to begin Phase 1 development in H1 2026 and has received FDA IND clearance [8, 58] - GLIX1 enhances TET2 activity, leading to increased 5hmC levels and double-stranded DNA breaks in cancer cells, ultimately causing cell death [19, 24] - Preclinical data indicates GLIX1 shows efficacy in various cancer cell lines and addresses key challenges for GBM drug development, including good blood-brain barrier penetration [30, 44, 49] - A Phase 1/2a clinical trial for GLIX1 in recurrent and progressive GBM is expected to initiate in Q1 2026, with potential expansion cohorts for newly diagnosed GBM and combination therapy with PARPi [55, 57] Motixafortide and APHEXDA - APHEXDA (motixafortide) has been successfully developed and out-licensed for stem cell mobilization in multiple myeloma [4] - License agreements for APHEXDA include up to $87 million in commercial milestones and royalties on sales from 18%-23% in Asia, and up to $200 million in commercial milestones with tiered double-digit royalties on sales outside of Asia (excluding solid tumors) [5, 6] - In first-line PDAC, the Chemo4MetPanc pilot phase 2 clinical trial showed a 64% Overall Response Rate and a median PFS of 96 months [84, 89] - The Chemo4MetPanc randomized phase 2b clinical trial is ongoing, equally funded by Regeneron and BioLineRx, with full enrollment planned in 2027 [90, 94] Financial Status - The company reported cash of approximately $282 million as of June 30, 2025, with a cash runway into the first half of 2027 [96]

Core Insights - BioLineRx Ltd. is making progress in evaluating assets for potential pipeline expansion in oncology and rare diseases, with a targeted transaction for 2025 [1][2] - The company has a strong balance sheet with $28.2 million in cash as of June 30, 2025, extending its cash runway into the first half of 2027 [3] - The CEO expressed confidence in executing a transaction this year to expand the pipeline and create long-term value [2] Financial Updates - Total revenues for Q2 2025 were $0.3 million, primarily from royalties related to APHEXDA, compared to $5.4 million in Q2 2024 [14][21] - Research and development expenses for Q2 2025 were $2.3 million, slightly up from $2.2 million in Q2 2024 [14][21] - The net loss for Q2 2025 was $3.9 million, a significant decline from a net income of $0.5 million in Q2 2024 [14][21] Clinical Updates - The ongoing CheMo4METPANC Phase 2b clinical trial is evaluating motixafortide in combination with cemiplimab and standard chemotherapy, with promising interim results [9] - In the treatment of metastatic pancreatic cancer, two patients showed significant responses, including one with complete resolution of liver lesions [4][5] - A Phase 1 clinical trial for motixafortide in sickle cell disease is progressing, with results expected in the second half of 2025 [10] Product Performance - APHEXDA generated sales of $1.7 million in Q2 2025, contributing $0.3 million in royalty revenue to BioLineRx [11] - The company has retained rights to develop motixafortide for metastatic pancreatic cancer, with a Phase 2b trial ongoing in collaboration with Columbia University [15][16]